uniQure N.V. Contract Liability (Deferred Revenue)
uniQure N.V. (QURE) had Contract Liability (Deferred Revenue) of $2.08 million as of 2020-12-31, per its 10-K filed 2022-02-25.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2022-02-25
- 2020-12-31: Contract with Customer, Liability, Current $2.08M.
- 2020-09-30: Contract with Customer, Liability, Current $7.67M.
- 2020-06-30: Contract with Customer, Liability, Current $6.15M.
- 2020-03-31: Contract with Customer, Liability, Current $6.73M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2020-12-31 | $2.08M 10-K · filed 2022-02-25 |
| 2020-09-30 | $7.67M 10-Q · filed 2020-10-27 |
| 2020-06-30 | $6.15M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $6.73M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $7.63M 10-K · filed 2021-03-01 |
| 2019-09-30 | $7.53M 10-Q · filed 2019-10-28 |
| 2019-06-30 | $7.22M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $7.77M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $7.63M 10-K · filed 2020-03-02 |
| 2018-09-30 | $8.59M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $8.46M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $9.70M 10-Q · filed 2018-04-30 |
| 2017-12-31 | $4.61M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |